AACR Conference Coverage
Featured Articles
(Johns Hopkins Medicine) Apr 3, 2019 - Due to advances in treatment, an ever-increasing number of patients are living longer as metastatic cancer survivors. They and their doctors face a host of new challenges that require immediate attention. It used to be when you were diagnosed with metastatic cancer, you were told to get your...
Read Article
(BMS) Apr 2, 2019 - Bristol-Myers Squibb Company today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab). In the pooled analysis of the four...
Read Article
Latest Articles
April 05, 2019
April 04, 2019
April 04, 2019
April 03, 2019
April 03, 2019
April 03, 2019
April 03, 2019
April 03, 2019
View More
News Commentary
Editor Image
03 Apr, 2019 | by H. Jack West, MD
Nice to see further long-term survival data, really in keeping with what we've...
View Comment
Editor Image
02 Apr, 2019 | by Tomasz M. Beer, MD
A badly misleading title. This study could not determine if survival is...
View Comment
View More
Featured Videos
There are no videos.
OBR Blog
Facts first, then comments. Keynote -189: This phase III trial compared pembrolizumab (pembro), or placebo, plus... Read more
April 17, 2018
A pre-meeting webinar provided a glimpse of some of the key presentations at the upcoming annual meeting of the... Read more
March 16, 2018

OBR Tweets

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl

Jul 01
At #ASCO’s virtual meeting, studies featured potentially practice-changing data. Among the studies were the BOSTON… https://t.co/6pXpxFomwu

Jun 22
Howard S. Hochster, MD: Another, but far more problematic approval for Pembro. Which tumors actually have high TMB… https://t.co/pBSquns9mN

Jun 19
Dean Gesme, MD: The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E… https://t.co/GXnYhO8jov

Jun 17
Thomas Marsland, MD: I actually enjoyed the experience. I certainly missed mingling with friends and colleagues. Al… https://t.co/gVtYjkzPzy

Jun 16
Derek Raghavan, MD, on @LevineCancer provides a general overview of prostate cancer therapies #ASCO20 https://t.co/niwz0yPHjB

Jun 16
H. Jack West, MD: We await phase 3 data, but many will welcome a new option with an approximately 35% response rate… https://t.co/Ld5N8KrWye

Jun 15
Nicholas Vogelzang, MD, FASCO, FACP, of @CCCNevada updates us on the status of PSMA-linked radiopharmaceuticals for… https://t.co/MoEkutc8VW

Jun 11
Edward Garon, MD, of @dgsomucla examines the ADAURA clinical study regarding adjuvant treatment in NSCLC #ASCO20 https://t.co/EEBPMbBOuo